149 related articles for article (PubMed ID: 15731776)
1. Type II collagen as specific marker for mesenchymal chondrosarcomas compared to other small cell sarcomas of the skeleton.
Müller S; Söder S; Oliveira AM; Inwards CY; Aigner T
Mod Pathol; 2005 Aug; 18(8):1088-94. PubMed ID: 15731776
[TBL] [Abstract][Full Text] [Related]
2. Small cell osteosarcoma of bone: an immunohistochemical study with differential diagnostic considerations.
Devaney K; Vinh TN; Sweet DE
Hum Pathol; 1993 Nov; 24(11):1211-25. PubMed ID: 7503935
[TBL] [Abstract][Full Text] [Related]
3. [Neoplastic chondroneogenesis as a characteristic of mesenchymal chondrosarcomas].
Schörle CM; Unni KK; Aigner T
Orthopade; 2002 Jun; 31(6):544-50. PubMed ID: 12149925
[TBL] [Abstract][Full Text] [Related]
4. NKX3.1 a useful marker for mesenchymal chondrosarcoma: An immunohistochemical study.
Syed M; Mushtaq S; Loya A; Hassan U
Ann Diagn Pathol; 2021 Feb; 50():151660. PubMed ID: 33302222
[TBL] [Abstract][Full Text] [Related]
5. Type II collagen, but not aggrecan expression, distinguishes clear cell chondrosarcoma and chondroblastoma.
Söder S; Oliveira AM; Inwards CY; Müller S; Aigner T
Pathology; 2006 Feb; 38(1):35-8. PubMed ID: 16484006
[TBL] [Abstract][Full Text] [Related]
6. FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma.
Lee AF; Hayes MM; Lebrun D; Espinosa I; Nielsen GP; Rosenberg AE; Lee CH
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):233-8. PubMed ID: 21084965
[TBL] [Abstract][Full Text] [Related]
7. Cell differentiation and matrix gene expression in mesenchymal chondrosarcomas.
Aigner T; Loos S; Müller S; Sandell LJ; Unni KK; Kirchner T
Am J Pathol; 2000 Apr; 156(4):1327-35. PubMed ID: 10751358
[TBL] [Abstract][Full Text] [Related]
8. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
9. Towards a new understanding and classification of chondrogenic neoplasias of the skeleton--biochemistry and cell biology of chondrosarcoma and its variants.
Aigner T
Virchows Arch; 2002 Sep; 441(3):219-30. PubMed ID: 12242518
[TBL] [Abstract][Full Text] [Related]
10. Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma.
Machado I; López Guerrero JA; Navarro S; Mayordomo E; Scotlandi K; Picci P; Llombart-Bosch A
Virchows Arch; 2013 Jun; 462(6):665-71. PubMed ID: 23681112
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal chondrosarcoma: an immunohistochemical study of 10 cases examining prognostic significance of proliferative activity and cellular differentiation.
Nussbeck W; Neureiter D; Söder S; Inwards C; Aigner T
Pathology; 2004 Jun; 36(3):230-3. PubMed ID: 15203726
[TBL] [Abstract][Full Text] [Related]
12. MIC2 detection in tumors of bone and adjacent soft tissues.
Devaney K; Abbondanzo SL; Shekitka KM; Wolov RB; Sweet DE
Clin Orthop Relat Res; 1995 Jan; (310):176-87. PubMed ID: 7641436
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular, extraskeletal mesenchymal chondrosarcoma.
Jain M; Puri V; Madan NK
Indian J Med Sci; 2011 Dec; 65(12):552-6. PubMed ID: 23548257
[TBL] [Abstract][Full Text] [Related]
14. OLIG2 Immunolabeling of Mesenchymal Chondrosarcoma: Report of 14 Cases.
Yao K; Duan Z; Yang S; Du Z; Wang Y; Qi X
J Neuropathol Exp Neurol; 2020 Sep; 79(9):959-965. PubMed ID: 32770197
[TBL] [Abstract][Full Text] [Related]
15. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors.
Wehrli BM; Huang W; De Crombrugghe B; Ayala AG; Czerniak B
Hum Pathol; 2003 Mar; 34(3):263-9. PubMed ID: 12673561
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas.
Yoshikawa H; Rettig WJ; Lane JM; Takaoka K; Alderman E; Rup B; Rosen V; Healey JH; Huvos AG; Garin-Chesa P
Cancer; 1994 Aug; 74(3):842-7. PubMed ID: 8039112
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of NKX2-2 expression in round cell sarcomas and other tumors with EWSR1 rearrangement: imperfect specificity for Ewing sarcoma.
Hung YP; Fletcher CD; Hornick JL
Mod Pathol; 2016 Apr; 29(4):370-80. PubMed ID: 26847175
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ETV4 and WT1 expression in CIC-rearranged sarcomas and histologic mimics.
Hung YP; Fletcher CD; Hornick JL
Mod Pathol; 2016 Nov; 29(11):1324-1334. PubMed ID: 27443513
[TBL] [Abstract][Full Text] [Related]
19. Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and beta-catenin, Sox9, and osteocalcin immunostaining of 22 cases.
Fanburg-Smith JC; Auerbach A; Marwaha JS; Wang Z; Rushing EJ
Hum Pathol; 2010 May; 41(5):653-62. PubMed ID: 20138330
[TBL] [Abstract][Full Text] [Related]
20. NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.
Yoshida KI; Machado I; Motoi T; Parafioriti A; Lacambra M; Ichikawa H; Kawai A; Antonescu CR; Yoshida A
Am J Surg Pathol; 2020 Jun; 44(6):719-728. PubMed ID: 31972596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
